Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck is pinning hopes on PAH drug Winrevair to boost its top line once Keytruda loses exclusivity. Merck’s stock is reasonably valued and buying this fundamentally strong company at the current ...

2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR ® (sotatercept) for reimbursement in ...

The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated sales of $149 million. Goldman reiterates the Buy rating for Merck ... that the drug is ...

and a slightly underwhelming post launch revenue figure of $70m for pulmonary arterial hypertension drug Winrevair, which Merck has suggested could be a ~$6bn peak revenue drug. Winrevair has ...

Merck's most important product is Keytruda, a cancer drug that has won approval ... a therapy for pulmonary arterial hypertension with a new mechanism of action. According to some analysts ...

Winrevair's approval for PAH treatment represents a significant opportunity for Merck to establish a strong presence in the cardiovascular market. The drug has generated considerable excitement ...

MilliporeSigma continued its march of manufacturing investments this year, revealing plans to pump $76 million into expanding ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the ...

However, recent developments suggest a strategic diversification beyond this blockbuster drug. The approval and launch of Winrevair (sotatercept) for pulmonary arterial hypertension (PAH) marks ...